Vanda Pharmaceuticals, a biopharmaceutical company based in Washington, DC, secured a win late last week when the US Court of Appeals for the Federal Circuit found a patent covering its schizophrenia drug to be patentable.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Vanda Pharmaceuticals, West-Ward Pharmaceuticals, Hikma, US Court of Appeals for the Federal Circuit, patent infringement
